Abstract 644P
Background
GQ1005 is an innovative anti-HER2 antibody-drug conjugate (ADC) processed through a novel, integrated and stable enzyme conjugation links DXd to engineered trastuzumab, the drug-to-antibody ratio is 4.
Methods
In the FIH phase 1a/1b study, patients(pts) of HER2 expressing/mutated metastatic solid tumors progressed from the standard of care were included. Dose escalation was ranged from 2 to 9.6 mg/kg (2, 4, 6, 7.2, 8.4 and 9.6 mg/kg). Safety and efficacy were investigated Q3W as well as in the expansion stage.
Results
By April 19th, 2024, 165 pts were enrolled (the median age 55 [range 34-74] with the median line of prior therapy 3 [range 1-11]), including 55 HER2 positive BC, 35 HER2 low BC, 43 HER2 exon19/20 mutant lung cancer and 26 HER2 expressing (IHC2+/3+) gastric cancer pts. The median exposure time of GQ1005 was 12.0 weeks (3.0-63.7). No DLT was observed up to the highest dose. Only 28 and 14 of the 153 safety evaluable pts had ≥ G3 TRAE (18.3%) and the drug related SAE (9.2%), respectively. TRAEs (>20%) are shown in the table. Tumor response was observed from 4 mg/kg. In 29 efficacy evaluable HER2 low BC pts with the median prior therapies of 3, ORR was 27.6% and DCR was 69.0%, mPFS was 10.4m (2.3-NA) and mDOR was 11.9m (6.1-NA). Of 15 efficacy evaluable HER2 positive GC pts, 14 received trastuzumab, 6 received other HER2 ADCs, and 4 received HER2 TKIs. ORR, DCR and 6-mo PFS rate were 33.3%, 80.0%, and 70.0%, respectively. AE profile of both cohorts was consistent with whole population. Only 1 ILD occurred in each cohort. Table: 644P
TRAEs (>20%) | All Grade n=153(%) | ≥ G3 n=153 (%) |
Nausea | 64 (41.8) | 0 |
AST increased | 63 (41.2) | 2 (1.3) |
Anemia | 52 (34.0) | 6 (3.9) |
ALT increased | 47 (30.7) | 1 (0.7) |
Leukopenia | 42 (27.5) | 3 (2.0) |
Thrombocytopenia | 39 (25.5) | 2 (1.3) |
Decreased appetite | 36 (23.5) | 1 (0.7) |
Neutropenia | 35 (22.9) | 1 (0.7) |
Vomiting | 32 (20.9) | 1 (0.7) |
Conclusions
GQ1005 demonstrates excellent safety profile and encouraging antitumor activity in HER2 expressing tumors, including heavily treated HER2 low BC and HER2 positive GC. Given the wider therapeutic window and the safer profile of GQ1005, a superior survival benefit could be expected from the patients treated with GQ1005. (Sponsored by GeneQuantum Healthcare (Suzhou) Co., Ltd.).
Clinical trial identification
NCT06154343.
Editorial acknowledgement
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Legal entity responsible for the study
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Funding
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Disclosure
C. Zhou: Financial Interests, Personal, Advisory role, Consulting fees: Innovent Biologics, Qilu, Hengrui, TopAlliance Biosciences Inc.; Financial Interests, Personal, Other, Payment or honoraria from: Eli Lilly China, Sanofi, Boehringer Ingelheim, Roche, Merck Sharp & Dohme, Qilu, Hengrui, Innovent Biologics, Alice, C-Stone, Luye Pharma, TopAlliance Biosciences Inc., Amoy Diagnostics, AnHeart. All other authors have declared no conflicts of interest.
Resources from the same session
621P - Phase II trial of encorafenib and binimetinib (E+B) in patients (pts) with BRAF-altered advanced solid tumors: Results of E+B cohort in the BELIEVE trial (NCCH1901)
Presenter: Yoshitaka Honma
Session: Poster session 01
622P - Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in solid tumors with KRAS G12C mutation: Results from a phase Ib/II study
Presenter: Zhengbo Song
Session: Poster session 01
624P - Belvarafenib in patients (pts) with BRAF class II or III alteration-positive tumours: TAPISTRY study
Presenter: Rafal Dziadziuszko
Session: Poster session 01
625P - Initial results from the phase I, first-in-human study of the covalent, PI3Kα inhibitor TOS-358 in patients with solid tumors, expressing PI3Kα mutations or amplifications
Presenter: Marwan Fakih
Session: Poster session 01
626P - Roginolisib (IOA-244), a first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with metastatic uveal melanoma
Presenter: Anna Di Giacomo
Session: Poster session 01
627P - Long-term efficacy and safety of larotrectinib in non-primary central nervous system (CNS) TRK fusion cancer
Presenter: Alexander Drilon
Session: Poster session 01
628P - Efficacy and safety of larotrectinib as first-line treatment for patients (pts) with TRK fusion cancer: An updated analysis
Presenter: David Hong
Session: Poster session 01
629P - Phase I study of pamiparib and cabozantinib in patients with metastatic solid tumors harboring homologous recombination deficiency (HRD)
Presenter: Siqing Fu
Session: Poster session 01